Alkermes plc. (ALKS): what the price requires

At today's price, Alkermes plc. (ALKS) is priced for today's economics sustained for ~8.3 years. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.

Generated: 2026-07-19 · Source: https://boothcheck.com/report/ALKS

Headline

FieldValue
TickerALKS
CompanyAlkermes plc.
Current price$51.68/sh
CompositionU.S. 93% / Ireland 0% / Rest of world 7%

What The Price Requires (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basiswhole-company
Operating margin today9.9%
Must persist for8.3y
Multiple paid67x operating income

Solve inputs: computed at a 7.6% cost of capital; growth searched up to the 25% self-funding ceiling; each 1pp moves the implied horizon ~2.4 years.

Reconcile: at the x-ray's 9.3% required return this reads ~12 years; the models below use their own rates.

How unusual the bet is: high

ReferenceValue
vs own history+1.40σ
cohort percentile (of 113 peers)97
sustained it ~8.3 years at this level24%
implied end-window share0%

Valuation X-Ray

Every valuation family lands below the price. The price therefore requires assumptions beyond what those standard frames encode.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset5.28x4expensive
Earnings7.62x3expensive
Relative1.82x3expensive
Growth1.47x3expensive

Families that call it expensive: Asset, Earnings, Relative

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 7.9%); the inversion above states its own rate.

Per-Model Detail (n=13)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth$23.822.17xyesFCF base $0.2B, growth 5% (input: historical growth), terminal g 4.0%, WACC 7.9%, 6yr projection
DCF Exit MultipleGrowth$40.511.28xyesExit EV/EBITDA: 44.7x / 46.7x / 48.7x (bear / base = today's held flat / bull), 6yr
Relative ValuationRelative$28.361.82xyesP/E 33.67x (blended: static sector reference 24x + trailing (TTM) 56x), scenarios: 28.2x / 33.7x / 39.2x (bear / base = reference held flat / bull), EV/EBITDA 25.2x
Simple DDMGrowth——no—
Two-Stage DDMGrowth——no—
Simple Excess ReturnAsset$9.935.20xyesBV/sh $10.54, ROE (TTM) 8.7%, ke 9.3%
Two-Stage Excess ReturnAsset$9.655.36xyes5yr excess ROE then converge to ke=9.3%
Discounted Future Market CapGrowth$35.141.47xyesRev $1.6B, growth 5% (input: historical growth; tapered), Terminal P/S: 4.6x / 5.5x / 6.4x (bear / base = today's held flat / bull, cap 8x)
Growth-Adjusted P/ERelative——no—
Margin TrajectoryGrowth——no—
Earnings Power ValueEarnings$2.7618.72xyesNormalized EBIT (5y avg op income, one-time charges added back) $0.18B × (1−21%) / WACC 7.9% → EPV (no growth)
Residual IncomeAsset$9.605.38xyesBV $10.54 + 5yr PV of (ROE (TTM) 8.7% − Kₑ 9.3%) × BV; BV grows 5.7%/yr
Graham NumberAsset$14.613.54xyes√(22.5 × EPS $0.90 × BVPS $10.54) — Graham's conservative floor
EV/EBITDA RelativeRelative$12.694.07xyesEBITDA $0.21B × sector EV/EBITDA 16.0x
FCF YieldEarnings$6.787.62xyesFCF $221.8M / Kₑ 9.3% — zero-growth perpetuity
SBC-Adj FCF YieldEarnings$0.015168.00xyesSBC-adj FCF $0.11B (FCF $0.22B − SBC $0.11B) capitalized at Kₑ (excluded from median)
Ben Graham FormulaEarnings$0.7568.91xyesEPS $0.90 × (8.5 + 2×-5.0%) × (4.4 / 5.3%) (excluded from median)
ROIC-Justified P/BAsset——no—
P/Sales SectorRelative$37.601.37xyesRevenue $1.56B × sector P/S 4.0x
PEG Fair ValueRelative——no—
Earnings YieldEarnings$9.735.31xyesEPS $0.90 / required return 9.3% (Rf 4.3% + ERP 5.0%)
Funds From Operations MultipleRelative——no—
Clinical Phase NPVGrowth——no—
MertonAsset——no—
V5 Mechanical———no—

Solvency

FieldValue
Net debt$1.0b
Net debt / NOPAT (after-tax)8.69x
Net debt / operating income (pre-tax)6.87x
Interest coverage7.1x
Share count CAGR (dilution)0.6%
Burning cashno

Bullet Takeaways

Bull Case

The most counterintuitive thing about Alkermes is that its operating margin could fall from here and the bet would still be intact. That sounds backward for a company trading at a large premium, but it is the structure of the thesis. The marketed psychiatry and addiction drugs already throw off cash, with product sales net of $1,184.6 million against $1,083.5 million the prior year, a $101.1 million gain. What the price is actually paying for is not a wider margin on those products. It is the orexin franchise the cash funds, where the company is developing "Alixorexton...a novel, investigational, oral, selective orexin 2 receptor agonist" for narcolepsy and beyond. A buyer here is underwriting a pipeline, with a profitable base business as the floor under it.

The pipeline read is improving, not stalling. Management reported a Phase 2 study in narcolepsy type 2, Vibrance-2, with 93 patients and a positive result, which the company frames as the first large Phase 2 to show benefit from an orexin-2 agonist in that population, and the Phase III Brilliance program is now enrolling. The orexin platform is also being pushed past sleep into ADHD and fatigue, with a proof-of-concept study expected to read out in the fourth quarter of 2026. When Eli Lilly entered the orexin space, Alkermes read it as external validation of the pathway rather than a threat, because a deep-pocketed entrant confirms the science is real and the commercial prize large.

The February 2026 Avadel acquisition reshaped the near-term story by adding a marketed asset. LUMRYZ, an approved once-nightly narcolepsy therapy, is now in the portfolio, and management guided LUMRYZ net sales of $315 million to $335 million for the period from February 12 through December 31, 2026. That turns the sleep franchise from a pure pipeline bet into a commercial business with a development engine attached, and it puts Alkermes in narcolepsy on both the marketed and the experimental side. The base business funds the science, the science has a real readout cadence, and the acquisition gives the company a foothold in the exact market its lead candidate targets.

Bear Case

The competitive picture is where the bear case starts, because Alkermes sells into markets that attract well-funded rivals and it is now developing in one of the most crowded races in neuroscience. The 10-K is blunt that "a number of companies currently market and/or are developing products to treat schizophrenia and/or bipolar I disorder that may compete with and negatively impact future sales of ARISTADA", and the same dynamic threatens VIVITROL, where "increased competition may lead to reduced unit sales of VIVITROL and increased pricing pressure". The marketed base that funds the pipeline is therefore not safe; it is a portfolio of branded drugs under pressure from new entrants and, eventually, generics, with the filing noting products "subject to Paragraph IV litigation in response to companies seeking to market generic versions".

The orexin bet, which is the whole reason the stock trades where it does, faces the deepest pocket in the industry. Eli Lilly's entry into orexin is validation of the science, but it is also a direct competitive threat: a company with vastly greater financial resources and commercial reach is now pursuing the same receptor target. Alkermes can be first or best, but it cannot outspend a competitor of that scale, and in a market where a single large rival can define the standard of care, being early is not the same as winning. The pipeline can read out positively and still lose commercially if a better-resourced entrant arrives close behind.

Then there is what the price requires, and it is steep. No valuation lens reaches $44.90. The asset and earnings-power methods land far below, with an earnings-power value near $5.83 and excess-return reads near $10, because they price only the demonstrated business. Even the forward-growth methods fall short: a perpetual-growth cash-flow read near $25 and an exit-multiple read near $36 both sit under the price. The price is a bet beyond what any standard frame supports, which means it leans almost entirely on the orexin program succeeding, on schedule, against Lilly. The balance sheet adds pressure: the Avadel deal pushed net debt to roughly $1 billion against gross debt of about $1.5 billion, with leverage near 5 times operating income, so the company took on debt to buy LUMRYZ at the same moment the pipeline needs heavy clinical spend. Interest coverage near 5.8 times is workable, but the combination of a debt-funded acquisition and a binary pipeline is the structural risk: if alixorexton disappoints, the methods that price the demonstrated business are the ones that turn out to be right, and there is a long way down to them.

Valuation

The price is built almost entirely out of expectation, and the cleanest way to see that is that none of the methods we use to triangulate reaches it. At $44.90 the shares are rich on assets, rich on earnings power, rich on peer multiples, and rich even against forward growth. That is unusual: most premium names have at least one family of method that defends the price. Here the asset lenses land near $10 on book-value-plus-profitability, the earnings-power lens lands near $5.83 capitalizing normalized operating profit, and the peer-multiple lens lands near $26 on a blended earnings multiple against the specialty-pharma sector. The forward-growth methods do the most to close the gap and still fall short, reaching the mid-$20s to mid-$30s. The price sits above all of them, which tells you the market is paying for something the trailing business does not contain.

What it is paying for is the orexin pipeline, and the inversion makes the shape of that bet concrete in a way that looks paradoxical at first. The price does not require Alkermes to widen its margin; it implies the company can run at a somewhat lower operating margin than the roughly 12% it earns today and still justify the value, provided the growth and its duration hold for years. In plain terms, the price is a wager on a long runway of new revenue from the pipeline, not on the existing drugs becoming more profitable. That is the right way to read a development-stage premium on top of a commercial base: the value lives in the readouts, not in the income statement as it stands.

Solvency frames how much room there is for the bet to take time. The Avadel acquisition moved the balance sheet to a net-debt position near $1 billion, with leverage around 5 times operating income and interest coverage near 5.8 times. That is manageable for a profitable specialty-pharma company, but it is no longer the cash-rich posture that would let the company absorb a pipeline setback without consequence. The share count has been essentially flat, so this is not a dilution story; it is a leverage-plus-pipeline story. The decisive question for the buyer is binary and external: alixorexton either delivers a competitive narcolepsy profile in Phase III or it does not, and the price has very little margin for the second outcome.

Catalysts

The first quarter of 2026 set the tone for a transition year. Alkermes reported revenue of $392.9 million and adjusted EBITDA of $80.3 million, with a GAAP net loss of $66.5 million that reflected the cost of the just-closed Avadel acquisition rather than an operating deterioration, and the company described the loss as narrower and the revenue stronger than expected. The acquisition itself is the headline corporate action: Alkermes completed the purchase of Avadel Pharmaceuticals in February 2026, adding the marketed narcolepsy therapy LUMRYZ, for which management guided net sales of $315 million to $335 million over the February-to-December 2026 period.

The clinical calendar is what moves the stock from here. The Phase III Brilliance program for alixorexton is enrolling narcolepsy type 1 and type 2 patients, a near-term idiopathic-hypersomnia readout for LUMRYZ is expected that could support a supplemental filing, and a proof-of-concept study in ADHD is expected to read out in the fourth quarter of 2026. Each readout is a discrete event with the potential to reprice the orexin thesis in either direction. With the stock priced beyond what the current business supports, the pipeline events, not the quarterly product sales, are the catalysts that matter.

Peer Cohorts (Per Segment, With Filing Citations)

Alkermes (consolidated) (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

Sources

Q1 FY2026 earnings call · Q1 FY2026 earnings release

View the full interactive ALKS report on boothcheck